The GLP-1 obesity market overall is projected to grow dramatically in 2026 and beyond, driven by reduced prices, expanded Medicare and Medicaid coverage, and the newfound accessibility of oral options
Introducing a second agent with a different mechanism can restart progress by circumventing the specific adaptations the body made in response to the first compound
One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis
Yet debate continues over who should use them and when
March 25, 2025: Food & Drug Administration Says Trulicity Shortage Still Active as Lawsuits Increase On February 21, 2025, the Food & Drug Administration lifted many of the semaglutide injection shortages